186 related articles for article (PubMed ID: 38062767)
21. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
[TBL] [Abstract][Full Text] [Related]
22. HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
Weeks AL; Wilson SG; Ward L; Goldblatt J; Hui J; Walsh JP
BMC Med Genet; 2016 Aug; 17(1):60. PubMed ID: 27530615
[TBL] [Abstract][Full Text] [Related]
23. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Semin Surg Oncol; 1999; 16(1):16-8. PubMed ID: 9890735
[TBL] [Abstract][Full Text] [Related]
24. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
25. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
Teng L; Deng W; Lu J; Zhang J; Ren X; Duan H; Chuai S; Duan F; Gao W; Lu T; Wu H; Liang Z
Oncotarget; 2017 Mar; 8(13):22023-22033. PubMed ID: 28423545
[TBL] [Abstract][Full Text] [Related]
26. Germ-line mutations in
Zhao Y; Yu T; Sun J; Wang F; Cheng C; He S; Chen L; Xie D; Fu L; Guan X; Yan A; Li Y; Miao G; Zhu X
Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34326253
[TBL] [Abstract][Full Text] [Related]
27. Whole Genome Sequencing of Familial Non-Medullary Thyroid Cancer Identifies Germline Alterations in MAPK/ERK and PI3K/AKT Signaling Pathways.
Srivastava A; Kumar A; Giangiobbe S; Bonora E; Hemminki K; Försti A; Bandapalli OR
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31614935
[TBL] [Abstract][Full Text] [Related]
28. Pathogenic germline variants in patients with endometrial cancer of diverse ancestry.
Liu YL; Gordhandas S; Arora K; Rios-Doria E; Cadoo KA; Catchings A; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Zhou Q; Iasonos A; Carrot-Zhang J; Manning-Geist B; Sia TY; Selenica P; Vanderbilt C; Misyura M; Latham A; Bandlamudi C; Berger MF; Hamilton JG; Makker V; Abu-Rustum NR; Ellenson LH; Offit K; Mandelker DL; Stadler Z; Weigelt B; Aghajanian C; Brown C
Cancer; 2024 Feb; 130(4):576-587. PubMed ID: 37886874
[TBL] [Abstract][Full Text] [Related]
29. An update on familial nonmedullary thyroid cancer.
Ammar SA; Alobuia WM; Kebebew E
Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
[TBL] [Abstract][Full Text] [Related]
30. Novel somatic alterations underlie Chinese papillary thyroid carcinoma.
Yang C; Xu W; Gong J; Liu Z; Cui D
Cancer Biomark; 2020; 27(4):445-460. PubMed ID: 32065787
[TBL] [Abstract][Full Text] [Related]
31. BRAF
Traversi F; Stooss A; Dettmer MS; Charles RP
Thyroid; 2021 May; 31(5):787-799. PubMed ID: 33012268
[No Abstract] [Full Text] [Related]
32. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
[TBL] [Abstract][Full Text] [Related]
33. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
34. Choice of control tissue impacts designation of germline variants in a cohort of papillary thyroid carcinoma patients.
Rubinstein JC; Nicolson NG; Rottmann D; Morotti R; Korah R; Carling T; Christison-Lagay ER
Ann Oncol; 2020 Jun; 31(6):815-821. PubMed ID: 32165204
[TBL] [Abstract][Full Text] [Related]
35. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon.
Xu B; Scognamiglio T; Cohen PR; Prasad ML; Hasanovic A; Tuttle RM; Katabi N; Ghossein RA
Hum Pathol; 2017 Jul; 65():133-139. PubMed ID: 28552827
[TBL] [Abstract][Full Text] [Related]
36. HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population.
Alzahrani AS; Murugan AK; Qasem E; Al-Hindi H
Thyroid; 2016 May; 26(5):667-71. PubMed ID: 26906432
[TBL] [Abstract][Full Text] [Related]
37. Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Associated Tumors-A Cohort Study.
Aswath K; Welch J; Gubbi S; Veeraraghavan P; Avadhanula S; Gara SK; Dikoglu E; Merino M; Raffeld M; Xi L; Kebebew E; Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne); 2021; 12():653401. PubMed ID: 34326811
[TBL] [Abstract][Full Text] [Related]
38. Rare germline variants in DNA repair-related genes are accountable for papillary thyroid cancer susceptibility.
Mio C; Verrienti A; Pecce V; Sponziello M; Damante G
Endocrine; 2021 Sep; 73(3):648-657. PubMed ID: 33821390
[TBL] [Abstract][Full Text] [Related]
39. Germline Mutations in Familial Papillary Thyroid Cancer.
Sarquis M; Moraes DC; Bastos-Rodrigues L; Azevedo PG; Ramos AV; Reis FV; Dande PV; Paim I; Friedman E; De Marco L
Endocr Pathol; 2020 Mar; 31(1):14-20. PubMed ID: 32034658
[TBL] [Abstract][Full Text] [Related]
40. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
